C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 31/70 (2006.01) A61K 38/17 (2006.01) A61K 48/00 (2006.01) C07K 14/47 (2006.01) C07K 16/18 (2006.01) C12Q 1/68 (2006.01) G01N 33/53 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2253541
The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of gipl, or anti-GIPL antibodies which specifically bind to the polypeptide, GIPL.
L'invention concerne un polynucléotide (gipl) dont on a isolé la séquence partielle à partir d'une banque d'ADNc PHD-1 et qui identifie et code un nouvel inhibiteur de phospholipase (GIPL) de l'homme. L'invention concerne des vecteurs d'expression obtenus par génie génétique et des cellules hôtes comprenant la séquence d'acides nucléiques codant GIPL. Elle concerne également l'utilisation de GIPL purifié et de ses agonistes dans des compositions pharmaceutiques servant à traiter des maladies associées à une activité anormale ou excessive de phospholipase. Elle concerne, de plus l'utilisation de molécules antisens par rapport à gipl ou des inhibiteurs de GIPL dans des compositions pharmaceutiques servant à empêcher la grossesse ou à traiter la maladie d'Alzheimer. Elle concerne également des méthodes diagnostiques mettant en application des compositions diagnostiques contenant le polynucléotide, ses fragments ou son complément, qui s'hybrident avec la séquence génomique ou la transcription de gipl, ou des anticorps anti-GIPL qui se fixent de façon spécifique ou polypeptide de GIPL.
Hawkins Phillip R.
Murry Lynn E.
Incyte Genomics Inc.
Incyte Pharmaceuticals Inc.
Smart & Biggar
LandOfFree
Human phospholipase inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human phospholipase inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human phospholipase inhibitor will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1969056